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In a prospective study of 36728 women and 35688 men during 18 years of follow-up, compared to systolic pressure o130mm Hg,
levels of 130–149, 150–169 and X170mm Hg in women were associated with relative risks of renal cell cancer of 1.7, 2.0 and 2.0,
respectively (P for linear trend, 0.11). In men, there was no association with blood pressure.
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The association of blood pressure with risk of renal cell cancer has
been investigated in a number of cohort (Fraser et al, 1990; Grove
et al, 1991; Coughlin et al, 1997; Heath et al, 1997; Chow et al, 2000;
Choi et al, 2005; Flaherty et al, 2005; Fryzek et al, 2005; Lindgren
et al, 2005; Schouten et al, 2005) and case–control (McLaughlin
et al, 1995; Yuan et al, 1998; Shapiro et al, 1999) studies, using
as principal exposure variable either recorded blood pressure or
reported hypertension. In men, recorded blood pressure has
shown a convincing exposure–response gradient related to renal
cell cancer risk (Coughlin et al, 1997; Chow et al, 2000). In women,
however, only reported history of hypertension has been studied as
the main exposure variable. In one cohort (Flaherty et al, 2005)
and two case–control studies (Yuan et al, 1998; Shapiro et al,
1999), history of hypertension was associated with increased risk.
Documenting the presence or the lack of an exposure–response
gradient in women is important, and might promote a better
probing of the underlying mechanism of the association.
In this prospective study of 36728 women and 35688 men, we
report on the association of blood pressure measured at baseline
with renal cell cancer risk during 18 years of follow-up, together
with that related to ever use of blood pressure medication.
MATERIALS AND METHODS
In 1984, 85100 individuals were invited to the Nord Trøndelag Health
Study (the HUNT Study) in Norway, and 75058 (88.2 percent)
accepted the invitation, filled in a self-administered questionnaire,
and attended a clinical examination (Holmen et al, 1991; Ellekjaer
et al, 2000). Briefly, information included smoking status and
standardised measurements of blood pressure, body height and
weight. The study was approved by the Regional Committee for Ethics
in medical research, and by the Norwegian Data Inspectorate.
This study was restricted to participants without prevalent
cancer who had complete information on blood pressure and body
mass index. Blood pressure was measured using calibrated
mercury manometers with standard cuff size (Holmen et al,
1991). We divided systolic pressure (in mm Hg) into the following
categories: o130 (reference), 130–149, 150–169 and X170, and
diastolic pressure (in mm Hg) into the following: o85 (reference),
85–94, 95–104 and X105. Information on use of antihypertensive
medication was derived from the question ‘do you use or have you
ever used blood pressure medication?’
Body mass index was calculated as weight (in kg) divided by the
squared value of height (in metres), and grouped into four
categories: o18.5, 18.5–24.9, 25–29.9 and X30. Information on
smoking was categorised as never, former or currently smoking.
Education was divided into three categories, depending on
duration (o9, 10–12 and 412 years).
The mandatory reporting of cancer by physicians and hospitals
to the Cancer Registry of Norway (www.kreftregisteret.no)
provides information on incident cases of renal cell cancer that
occurred during follow-up. Person-years were calculated from the
clinical examination until the diagnosis of renal cell cancer or
other cancers (except basal cell carcinoma), death from other
causes, or the end of follow-up, 31 December 2002, whichever
came first. The relative risk was calculated as the rate of renal cell
cancer within a given blood pressure category compared with that
in the reference category. We used Cox regression analysis to
adjust for potential confounding by body mass index, smoking,
use of blood pressure medication and education level. The
statistical analyses were conducted using STATA, version 9.0
(StataCorp LP, 1985–2005).
RESULTS
During 18 years of follow-up, 94 women and 144 men were
diagnosed with renal cell cancer. Characteristics of the cohort are
shown in Table 1. Risk was much lower in women with systolic
pressure below 130mm Hg than for those with higher levels, after
adjustment for age, body mass index, smoking status, use of blood
pressure medication and education (Table 2). Compared to the
reference (o130mm Hg), the adjusted relative risk in women with
systolic pressure 130–149mm Hg was 1.7 (95% confidence interval
(CI), 0.9–3.5), with levels 150–169mm Hg the risk was 2.0 (95%
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4.6). For diastolic pressure, the association with renal cancer risk
was weaker than for systolic. Compared to the reference (o85mm
Hg), the adjusted relative risk in women with diastolic pressure
X105mm Hg was 1.6 (95% CI, 0.8–3.5).
In a separate analysis restricted to people who reported never-
use of blood pressure medication at baseline, there was a strong
and positive association between systolic pressure and risk among
women (Table 3). Thus, the adjusted relative risk in women with
systolic pressure X170mm Hg compared with o130mm Hg was
3.4 (95% CI, 1.3–8.9), and it showed a significant trend with
increasing systolic pressure (P for trend, 0.001); diastolic pressure
among never users of blood pressure medication, however, showed
similar associations to the overall results.
Use of antihypertensive medication, as reported by women at
baseline, showed a weak positive association (adjusted relative
risk, 1.4, 95% CI, 0.8–2.2, Table 2). In men, there was no clear
association with systolic or diastolic blood pressure (Tables 2
and 3), and none between blood pressure medication and risk
(Table 2).
DISCUSSION
The most striking finding in this study was that normotensive
systolic blood pressure among women (o130mm Hg) was
associated with consistently lower risk for renal cell cancer than
higher levels. No previous study of women has assessed the effect
of measured blood pressure on this risk, but a positive association
with recorded blood pressure has been found among men
(Coughlin et al, 1997; Chow et al, 2000).
Correspondingly, studies of antihypertensive medication, or
history of hypertension, have not shown consistent results. In two
prospective studies, antihypertensive treatment was associated
with higher risk of renal cell cancer (Fraser et al, 1990; Heath et al,
1997), but others found no association (Grove et al, 1991; Flaherty
et al, 2005; Schouten et al, 2005). One large study linking
prescriptions and cancer registration in Denmark indicated that
antihypertensive medication may increase risk, but was inter-
preted as being due to confounding by underlying hypertension
(Fryzek et al, 2005). One prospective study (Flaherty et al, 2005)
and two case–control studies (Yuan et al, 1998; Shapiro et al,
1999) have also reported positive associations with a history of
hypertension.
Contrary to previous evidence, we found that measured blood
pressure, or use of blood pressure medication, was not associated
with risk for renal cell cancer among men. The reason for this
discrepancy is not obvious, but may be the play of chance.
In our study, systolic and diastolic blood pressures were
measured according to standardised procedures by a team of
trained nurses. The cohort consists of the majority of adults in a
stable, homogeneous population in Norway, well suited for cancer
Table 1 Characteristics of the study population (36728 women and 35688 men), stratified by systolic blood pressure categories
Women Men
Systolic blood pressure Systolic blood pressure
Characteristic o130 130–149 150–169 X170 o130 130–149 150–169 X170
No. of participants 17745 9251 5292 4440 12209 14333 5954 3192
No. of renal cell cancers 13 26 24 22 31 40 35 18
Median person years (range) 18 (19) 18 (19) 17 (19) 13 (19) 18 (19) 18 (19) 17 (19) 10 (19)
Mean age at baseline, years (s.d.) 39 (13) 52 (16) 63 (13) 70 (10) 42 (14) 46 (16) 57 (16) 67 (12)
Mean age at diagnosis, years (s.d.) 60 (15) 72 (12) 73 (10) 75 (9) 65 (12) 64 (14) 73 (9) 79 (8)
Body mass index, % X25.0kgm
 2 25 52 64 70 37 51 62 62
Smoking status, % current 34 23 15 10 32 29 26 24
Educational level, % X13 years 11 5 2 1 13 10 5 3
Table 2 Relative risk of renal cell cancer associated with standardised measured blood pressure and self reported blood pressure medication
Women Men
Variable Person years Cases RR
a 95% CI Ptrend
b Person years Cases RR
a 95% CI Ptrend
b
Systolic blood pressure (mm Hg)
o130 304754 13 1.0 (Reference) — 200863 31 1.0 (Reference) —
130–149 145513 26 1.7 (0.9–3.5) — 223960 40 0.8 (0.5–1.4) —
150–169 73828 24 2.0 (0.9–4.2) — 81183 35 1.2 (0.7–2.0) —
X170 53060 22 2.0 (0.9–4.6) 0.11 33890 18 1.0 (0.5–1.9) 0.59
Diastolic blood pressure (mm Hg)
o85 346610 31 1.0 (Reference) — 264778 41 1.0 (Reference) —
85–94 145246 22 0.8 (0.5–1.5) — 173219 56 1.6 (1.0–2.3) —
95–104 64349 22 1.4 (0.8–2.5) — 76975 20 1.0 (0.6–1.7) —
X105 20950 10 1.6 (0.8–3.5) 0.13 24924 7 0.9 (0.4–2.0) 0.49
Blood pressure medication
c
No 504135 57 1.0 (Reference) — 499677 106 1.0 (Reference) —
Yes 73020 28 1.4 (0.8–2.2) — 40219 18 1.1 (0.6–1.8) —
CI¼confidence interval, RR¼relative risk.
aAdjusted for age, blood pressure medication (no, yes), body mass index (o18.5, 18.5–24.9, 25.0–29.9, X30.0), smoking status
(never, former, current, unknown), education (o10, 10–12, X13 years, unknown).
bP-values from trend test using the categories as an ordinal variable in the Cox regression
model.
cAdjusted for age, body mass index (o18.5, 18.5–24.9, 25.0–29.9, X30.0), smoking status (never, former, current, unknown), education (o10, 10–12, X13 years,
unknown).
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and the unique identification number allocated to each citizen.
Angiogenic and other growth factors are associated with blood
pressure increase, and may also be involved in the development of
renal cell cancer (Schena et al, 1999; Chow et al, 2000; Choueiri
et al, 2006). Thus, subtle long-term influences on renal function
may lead to hypertension and also be related to tumour growth.
The findings raise the possibility that high blood pressure may be a
cause of renal cell cancer.
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